Zurück zu Projekte

16639.1 PFLS-LS

Assessment of a drug candidate for the treatment of two rare orphan diseases: Morquio type B disease and GM1 gangliosidosis

Zusammenfassung

Assessment of a drug candidate for the treatment of two rare orphan diseases: Morquio type B disease and GM1 gangliosidosis

Weitere Texte

Abstract

Morquio type B disease and GM1 gangliosidosis are two rare orphan genetic disorders caused by mutated forms of the enzyme beta-galactosidase. A selective beta-galactosidase inhibitor was identified as a potential rescuer of the mutated enzyme as it helps the folding of the enzyme in vitro. The current project proposes to synthesize this potent drug with improved routing, to measure its efficacy on patient cells and to assess its in vivo bioavailability.

Beteiligte

Julie Charollais-Thoenig

Wirtschaftspartner

charollais@dorphan.com

Dorphan SA CHE-407.871.618 Julie Charollais-Thoenig Chemin de l'Eglise 7 1066 Epalinges VD CH

Roger Marti

Kontaktperson

roger.marti@hefr.ch

HEIA-FR Haute Ecole d'ingénierie et d'archi de Fribourg Roger Marti Boulevard de Pérolles 80 1700 Fribourg FR CH

Projektdetails

Forschungsstelle
INNOSUISSE
Projektstatus
Abgeschlossen
Projekttyp
Forschungsprojekt
Startdatum
2014-07-31
Enddatum
2015-11-30
Bewilligte Gesamtkosten
CHF 156225.00
Sektion
20 Förderbereich Life Sciences
NABS Politikbereich
Industrielle Produktivität und Technologie

Forschungsdisziplinen

  • T115 Medical technology 100.0%